Danaher names insider Julie Sawyer Montgomery as CEO
DHR•Recent business trends
- Danaher, which makes tools used in developing and testing medicines, cut its full-year core revenue growth forecast last month and reported weaker-than-expected revenue in its biotechnology business.
- The results contrasted with improving trends in the life sciences tools market as biotech and pharmaceutical companies increase spending on research and manufacturing following a prolonged post-pandemic slowdown.
Danaher appoints new CEO
Aug. 3 (Reuters) - Life sciences firm Danaher said on Monday it has appointed insider Julie Sawyer Montgomery as its CEO, succeeding Rainer Blair, effective October 1.
Blair will retire and serve as a senior adviser until March 31, 2027, it said, adding that there is no change to its previously announced third-quarter and full-year forecast.
Background on Montgomery and recent moves
- Sawyer Montgomery, who joined Danaher in 2017, has played a key role in transforming its diagnostics platform from about $6 billion in revenue at the time to nearly $11 billion today.
- She has also led the recent buyout of Masimo, best known for the devices hospitals use to measure blood-oxygen levels, and the pending acquisition of StatLab, a medical products maker.
